InjectionClinical Overview
Carboplatin Injection (150mg, 450mg) is a second-generation platinum antineoplastic agent on the WHO Model List of Essential Medicines. It incorporates a bidentate cyclobutanedicarboxylate leaving group that slows activation kinetics, producing DNA crosslinks similar to cisplatin but with dramatically reduced nephrotoxicity, ototoxicity, and emetogenicity. Dosing is individualized using the Calvert formula: Total Dose (mg) = Target AUC × (GFR + 25). Indicated for initial and palliative chemotherapy of advanced ovarian carcinoma, small cell lung cancer, non-small cell lung cancer, and head and neck neoplasms.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Administer intravenously only over 15 to 60 minutes diluted in 5% Dextrose or 0.9% NaCl. Calculate dose using the Calvert formula based on patient's GFR. Cycles typically repeat every 4 weeks. Vigorous pre-hydration is not routinely required unlike cisplatin.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Dose-limiting myelosuppression (severe thrombocytopenia with nadir at days 21-28, neutropenia, anemia), nausea, vomiting, asthenia, alopecia. Rare/Severe: Hypersensitivity reactions (risk increases after 6+ cycles), secondary acute leukemia, and neurotoxicity.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black Box Warning: Bone marrow suppression is dose-limiting, especially thrombocytopenia; monitor CBC with platelet count weekly. Black Box Warning: Anaphylaxis/severe allergic reactions (erythema, bronchospasm, hypotension), particularly in patients previously exposed to platinum therapy. Adjust dose strictly according to renal function.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, oncological diagnosis, or chemotherapy protocol guidance. Cancer therapies require specialized administration under the direct supervision of a registered medical oncologist in an accredited healthcare facility.